VYNE Therapeutics Inc.

VYNE · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$40-$28-$23-$73
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$2
Stock-Based Comp.$3$3$4$8
Change in WC$5$0$2$5
Other Non-Cash-$2-$0-$13$2
Operating Cash Flow-$34-$25-$29-$56
Investing Activities
PP&E Inv.-$0$0$0$0
Net Acquisitions$0$5$16$0
Inv. Purchases-$61-$62$0$0
Inv. Sales/Matur.$84$0$0$1
Other Inv. Act.$0$0$0$0
Investing Cash Flow$23-$57$16$1
Financing Activities
Debt Repay.$0$0$0-$36
Stock Issued$0$83$1$76
Stock Repurch.-$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$0$0$0
Financing Cash Flow-$0$82$2$40
Forex Effect$0$0$0$0
Net Chg. in Cash-$11-$0-$12-$16
Supplemental Information
Beg. Cash$31$31$43$58
End Cash$20$31$31$43
Free Cash Flow-$34-$25-$29-$56
VYNE Therapeutics Inc. (VYNE) Financial Statements & Key Stats | AlphaPilot